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Tocilizumab, a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody, is beneﬁcial for treating autoimmune
conditions such as rheumatoid arthritis (RA). The most common adverse event is upper respiratory tract infection; ocular side
eﬀects are rare. We describe a case of skin ulceration and bilateral retinopathy with multifocal cotton-wool spots and retinal
hemorrhages in a patient with RA treated with tocilizumab. Tocilizumab administration increased the serum level of IL-6
without aﬀecting the IL-8 levels. We could not exclude the possibility of blood coagulation or retinal vascular changes caused
by tocilizumab. The current case highlights the need to consider that ocular adverse eﬀects can develop in patients treated with
tocilizumab.
1.Introduction
Interleukin-6 (IL-6) is an immunoregulatory cytokine that
plays an important role in autoimmunity. Signaling abnor-
malities in IL-6 could lead to an autoimmune disease
or increased susceptibility to infection [1]. Tocilizumab
(Actemra, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan),
a humanized anti-human IL-6 receptor (IL-6R) monoclonal
antibody that inhibits IL-6 binding to IL-6R might inhibit
the biologic function of IL-6, which plays a pivotal role in
the pathogenesis of autoimmune diseases. Recent reports
have indicated that tocilizumab also may be beneﬁcial for
treating autoimmune diseases such as rheumatoid arthritis
(RA), Castleman’s disease, and juvenile idiopathic arthritis
[1–4]. The most common adverse events associated with the
drug are upper respiratory tract infections; however, some
serious adverse events have been reported previously [2–5]
andocularside eﬀectsareespeciallyrare[6,7].Wereportthe
case of a patient with RA who was treated with tocilizumab
and developed bilateral retinopathy with multiple cotton-
wool spots and bilateral retinal hemorrhages.
2.CaseReport
The patient was a 43-year-old woman who had been diag-
nosed with RA 9 years previously. Before tocilizumab was
administered intravenously, she had been treated with an
8-mg weekly dose of methotrexate, and the disease activity
was well controlled. However, after 15 months of treatment,
the RA was refractory to treatment and she was referred
to our hospital. At baseline, the disease activity score in 28
(DAS28) joints was 2.39. She had no complications such as
diabetes, hypertension, or systemic viral infections. Routine
ophthalmologic examinations, including measurement of
the best-corrected visual acuity (BCVA) and intraocular
pressure, slit-lamp examination, and fundus examination,
were unremarkable.
The patient received 8mg/kg tocilizumab intravenously
while she was in the hospital. Table 1 shows her laboratory
data on the day of treatment. Twenty days after treatment,
rashes inexplicably developed on the palms and planta pedis
that resembled pustulosis palmoplantaris, stomatitis on the
tongue, and diﬀuse pruritic erythema around the lumbar2 Case Reports in Rheumatology
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Figure 1: Adverse events after tocilizumab therapy. (a), (b) Photographs show the bilateral fundus images of retinopathy with bilateral
multiple cotton-wool spots and retinal hemorrhages around the optic disc. (c), (d), and (e) Rashes on the palms and planta pedis
resemble pustulosis palmoplantaris, and (f) diﬀuse pruritic erythema around the lumbar region appeared 20 days after the ﬁrst infusion
of tocilizumab. (g) Skin ulceration on the right external malleolus appeared immediately after the second infusion of tocilizumab.
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Figure 2: Four months after tocilizumab was discontinued and antibiotic therapy was started, (a, b) ocular ﬁndings and (c, d) rashes on the
palm and planta pedis are improving gradually. The ulcerative infected skin lesions gradually resolved (e), (f), and (g). (e) Two days after
debridement. The skin lesions resolved (f) 4 and (g) 9 months after discontinuation of tocilizumab.
region (Figures 1(c)–1(f)). The skin lesions showed no signs
of infection, and tocilizumab was continued. Immediately
after a second infusion, a skin ulcer developed on the right
external malleolus (Figure 1(g)). Four weeks after the sec-
ond tocilizumab administration, this area became necrotic.
She was treated with alprostadil alfadex (Prostandin, Ono
PharmaceuticalCo.,Ltd.,Osaka,Japan)andiodineointment
afterthenecrotictissuewasdebrided.Methicillin-susceptible
Staphylococcus aureus was cultured from the lesion.
Laboratory analyses of blood samples showed no abnor-
malities except an elevated serum C-reactive protein value
(3.01mg/dL). A chest X-ray and chest computed tomog-
raphy images were normal. The tuberculin skin test and
the QuantiFERON test (Cellestis Limited, Carnegie, VIC,
Australia) were negative. There was no sign of infectious
endocarditisoncardiacultrasonography.Abiopsyoftheskin
ulcers 2 months after tocilizumab administration showed
no apparent vasculitis, microangiopathy, or embolus. The
joint swelling and tenderness worsened and the DAS28
score 2 months after tocilizumab treatment increased to
5.69. At this time, the BCVA was 20/15 bilaterally. No
signiﬁcant inﬂammation was seen in the anterior segment.
No inﬂammatory cells in the vitreous or vasculitis were seen;
however, the fundus examination showed multiple cotton-
wool spots and retinal hemorrhages surrounding the optic
disc bilaterally (Figures 1(a) and 1(b)).
After tocilizumab was discontinued, antibiotic therapy
(systemic cefcapene pivoxil hydrochloride hydrate (300mg
three times daily) for 3 weeks) and oral prednisolone (up to
30mg/day) gradually ameliorated the necrotic tissue forma-
tion on the skin ulcers (Figures 2(c)–2(g)). The prednisolone
was tapered by 5mg/month to 5mg/day. The ocular ﬁndingsCase Reports in Rheumatology 3
0
10
20
30
40
50
First visit
IL-6
IL-8
(
n
g
/
m
L
)
after ﬁrst
tocilizumab
1 month
after second
tocilizumab
10 months
tocilizumab
4 months
after second
Figure 3: Serum concentrations of IL-6 and IL-8 before and after
tocilizumab administration.Marked increases intheserum levels of
IL-6 are observed 1 and 4 months after tocilizumab administration
that did not aﬀect the serum levels of IL-8.
improved concurrently with resolution of the skin lesions;
thecotton-woolspots remained, buttheretinal hemorrhages
gradually resolved 4 months after treatment (Figures 2(a)
and 2(b)). The patient’s disease activity improved and skin
ulceration showed complete epithelialization (Figure 2(g)).
Her DAS28 score 3 months after tocilizumab administration
decreased to 0.21. We also examined the serum levels of
IL-6 and IL-8 before and after tocilizumab administration.
The changes in these molecules are shown in Figure 3.W e
found markedly increased serum levels of IL-6 at 1 and 4
months after tocilizumab administration that did not aﬀect
the serum levels of IL-8.
3. Discussion
Tocilizumab has anti-inﬂammatory properties by inhibiting
IL-6 signaling, and the drug is beneﬁcial for treating
autoimmune conditions such as RA. The most common
adverse event reported has been mild upper respiratory tract
infection such as nasopharyngitis. We described, for the
ﬁrst time, fundus manifestations associated with tocilizumab
infusions, that is, bilateral retinopathy with multifocal
cotton-wool spots and retinal hemorrhages. Concerning the
vasculitis caused by biologics, previous investigators have
reported that vasculitis can occur after administration of
antitumor necrosis factor-α antibody [8, 9]. IL-6 exacer-
bates blood coagulation. As a result, binding inhibition
of IL-6 with IL-6R via tocilizumab administration causes
an excessive increase of IL-6, suggesting that peripheral
thrombosis might result [5] .T h ee x c e s s i v ei n c r e a s eo fs e r u m
IL-6 was conﬁrmed by the active fundus changes in the
current case. Therefore, fundus and histologic examinations
revealed no vascular changes; however, we could not exclude
Table 1: Laboratory data for the patient.
Property Value
WBC 5970
Neutro 85.6%
Lymph 7.9%
Mono 5.9%
Eosino 0.6%
Baso 0%
RBC 3.47 × 106 μL
HGB 10.9g/dL
PLT 239 × 103 μL
TP 7.1g/dL
ALB 3.4g/dL
BUN 10mg/dL
Cr 0.42mg/dL
Na 137mEq/L
K 4.1mEq/L
AST 23U/L
ALT 22U/L
LDH 229U/L
CRP 0.88mg/dL
C3 196mg/dL
C4 14mg/dL
IgG 1,840mg/dL
RF 683IU/mL
WBC: white blood cell; Neutro: neutrophil; Lymph: lymphocyte; Mono:
monocyte; Eosino: eosinophil; Baso: basophil; RBC: red blood cell; HGB:
hemoglobin; PLT: platelet; TP: total protein; ALB: albumin; BUN: blood
urea nitrogen; Cr: creatinine; ALT: aspartate aminotransferase; ALT: alanine
aminotransferase;LDH:lactatedehydrogenase;CRP:C-reactiveprotein;C3:
complement 3; C4: complement 4, IgG: immunoglobulin; RF: rheumatoid
factor.
the possibility of blood coagulation or immune complex
mediated vasculitis in this patient.
The occurrence of ocular adverse events associated with
tocilizumab therapy indicates involvement of the infectious
skin ulcers and direct involvement of tocilizumab, or both.
Wehavetoconsiderbothpossibilities.Apossibleexplanation
for the infection is that there was no evidence of vasculitis in
theskinbiopsyandocularexaminations.Theocularﬁndings
markedly improved concurrently with resolution of the skin
lesions with antibiotic therapy. This possibility is supported
by a report of ocular ﬁndings that were similar to the ocular
manifestations of infectious endocarditis [10]. Regarding
the direct involvement of tocilizumab, the drug itself might
directly aﬀect the retinal vascular endothelial cells by impair-
ing the retinal microcirculation as with interferon therapy
[11, 12]. Modiﬁcation of leukocyte adhesion to the vascular
endothelial cells and retinal capillary occlusion might have
caused the vascular changes in our patient.
The current case highlights the fact that ocular adverse
events should be considered in patients treated with
tocilizumabandsuggeststhatanalysestodetectinfectionand
vascular changes are important for diagnosing and treating
these conditions.4 Case Reports in Rheumatology
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